Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke.
about
Structure-function analysis of water-soluble inhibitors of the catalytic domain of exotoxin A from Pseudomonas aeruginosaNitric oxide and peroxynitrite in health and diseaseCell-based therapy for acute organ injury: preclinical evidence and ongoing clinical trials using mesenchymal stem cellsStructure of human tankyrase 1 in complex with small-molecule inhibitors PJ34 and XAV939Another "string to the bow" of PJ34, a potent poly(ADP-Ribose)polymerase inhibitor: an antiplatelet effect through P2Y12 antagonism?Endonuclease G does not play an obligatory role in poly(ADP-ribose) polymerase-dependent cell death after transient focal cerebral ischemia.PolyADP-ribosylation is required for pronuclear fusion during postfertilization in mice.Requirement for Parp-1 and DNA ligases 1 or 3 but not of Xrcc1 in chromosomal translocation formation by backup end joining.NAD+ loss, a new player in AhR biology: prevention of thymus atrophy and hepatosteatosis by NAD+ repletion.Contributions of poly(ADP-ribose) polymerase-1 and -2 to nuclear translocation of apoptosis-inducing factor and injury from focal cerebral ischemia.Mitochondrial dysfunction induces Sarm1-dependent cell death in sensory neuronsPostischemic poly (ADP-ribose) polymerase (PARP) inhibition reduces ischemia reperfusion injury in a hind-limb ischemia model.XRCC1 coordinates disparate responses and multiprotein repair complexes depending on the nature and context of the DNA damageSelective small molecule inhibition of poly(ADP-ribose) glycohydrolase (PARG).Alteration of poly(ADP-ribose) metabolism affects murine sperm nuclear architecture by impairing pericentric heterochromatin condensation.Poly(ADP-ribose) metabolism is essential for proper nucleoprotein exchange during mouse spermiogenesisPoly(ADP-ribose) polymerases PARP1 and PARP2 modulate topoisomerase II beta (TOP2B) function during chromatin condensation in mouse spermiogenesis.Molecular Mechanisms Underlying Cell Death in Spinal Networks in Relation to Locomotor Activity After Acute Injury in vitro.NAD+ depletion or PAR polymer formation: which plays the role of executioner in ischaemic cell death?Anti-inflammatory effects of PJ34, a poly(ADP-ribose) polymerase inhibitor, in transient focal cerebral ischemia in miceBlockade of PARP activity attenuates poly(ADP-ribosyl)ation but offers only partial neuroprotection against NMDA-induced cell death in the rat retinaMatrix Metalloproteinase-2 (MMP-2) Gene Deletion Enhances MMP-9 Activity, Impairs PARP-1 Degradation, and Exacerbates Hepatic Ischemia and Reperfusion Injury in Mice.Perinatal asphyxia: current status and approaches towards neuroprotective strategies, with focus on sentinel proteins.Pathogenesis of malaria and clinically similar conditions.Frataxin Deficiency Promotes Excess Microglial DNA Damage and Inflammation that Is Rescued by PJ34The Streptococcus pyogenes NAD(+) glycohydrolase modulates epithelial cell PARylation and HMGB1 releaseTRF2-RAP1 is required to protect telomeres from engaging in homologous recombination-mediated deletions and fusions.Inhibition of poly(adenosine diphosphate-ribose) polymerase by the active form of vitamin DTherapeutic applications of PARP inhibitors: anticancer therapy and beyondATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors.Mechanisms underlying cell death in ischemia-like damage to the rat spinal cord in vitroThe Sound of Silence: RNAi in Poly (ADP-Ribose) ResearchParthanatos: mitochondrial-linked mechanisms and therapeutic opportunities.Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase/gp91(phox) expression and the PARP-1/PAR pathway of apoptosisEnzyme-Regulated Supramolecular Assemblies of Cholesterol Conjugates against Drug-Resistant Ovarian Cancer Cells.Nicotinamide pre-treatment ameliorates NAD(H) hyperoxidation and improves neuronal function after severe hypoxia.Exclusive destruction of mitotic spindles in human cancer cells.Inhibition of poly(ADP-ribose) polymerase-1 or poly(ADP‑ribose) glycohydrolase individually, but not in combination, leads to improved chemotherapeutic efficacy in HeLa cells.Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.PARP1 depletion improves mitochondrial and heart function in Chagas disease: Effects on POLG dependent mtDNA maintenance.
P2860
Q24528153-BE051DC4-8609-4E48-90FB-246C004818A8Q24645400-BFAF801D-9D40-4330-B4AA-674910301301Q27026350-CCD6CD7C-C480-4576-8385-2ABE9C3B93ACQ27676990-9AACB820-BC3E-49BC-A6A3-DA83E31F0A23Q28543952-C8FFC03C-BB1D-46CA-8DBF-FC3B4E420548Q33567557-E0BFB284-9EB9-483B-A331-8D787CC6438FQ33686878-50296D9E-8323-42A9-8C31-C58BC7962509Q33698679-66258566-579F-4BCD-A4E0-B2E76F7B66FAQ33720228-635D568B-2B24-49E8-8BD1-96723C3E3AECQ33814677-3A3AB9E3-1991-4D79-8AA3-10631A7276B6Q33865342-3AD16BAC-1B00-4643-8BB0-1AC951ACA428Q33915402-B8BC660D-C751-4F0F-BC01-46C1E8F12C00Q33970153-3D1784FC-6FC9-49CB-B1BC-528BCC6629EEQ34119303-CD08AA36-4911-4A3B-A63E-FB3C8D999DB4Q34752415-5DF3BA67-814F-4D5E-931A-CF06D4A91776Q34764527-F4B01A59-501D-4EA6-846A-A5B229458FB5Q34826930-C85FE073-E9B7-4F68-BF69-CC9F9658002AQ35059282-1BD9641D-7288-4E48-93D1-BAD7306182F9Q35103426-96DA7CEF-426F-4EBE-BBCE-AE0F28DECD56Q35119919-C7003801-0D00-4B95-A2CF-92172946ED64Q35579560-92CB88D6-FA9A-486C-84E5-57B56D998A2CQ35768956-3667E121-09C1-4024-9B19-26B2E3F66792Q35795263-05DD9A42-356A-4933-A60B-D78CC15D09B8Q35838590-0E4E6ADF-7F3F-4EEE-9801-9D2C2E2678D8Q35949121-A3FF52B6-9CC9-4B92-8E8D-837E63502A26Q36219154-80D98F96-3530-4995-95DA-AF7B693B2DA0Q36670262-4E014267-6D57-489B-8DB7-4E1A568CB247Q36808300-FBE00695-C554-4C5A-A3DF-FF4572F52C30Q36853236-87FA73F7-3979-43C2-A976-B24B66A83365Q37059580-36BEDF53-84FD-414B-B4A0-B8FE66EAEB2FQ37062028-5DD526FB-EB45-4B31-8746-C0EE0F4D6C45Q37508170-1AB85F93-61C7-4687-B472-2333EEE0C9C8Q38200674-D2D88677-01A2-4F73-A5C5-39B1DF232319Q39355305-B84DBA06-B370-49BE-BBA7-FE28A5F9F712Q41006965-3B4C2A96-2D3A-4B65-93DA-62AADAD4B95AQ41914345-0472CCA0-7257-4DDE-9D72-9FD6261F715AQ42290806-93C08762-2D14-42AC-9A65-2EF0D57464E8Q43238750-2F7A2652-28A6-40D5-B246-4376C191432BQ48129205-B3521BF7-D295-4BF4-920D-00EBBFF5883EQ55416701-AF295EE1-2CCC-4F12-866A-6F8E7C38599A
P2860
Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Protective effects of PJ34, a ...... and in vivo models of stroke.
@ast
Protective effects of PJ34, a ...... and in vivo models of stroke.
@en
type
label
Protective effects of PJ34, a ...... and in vivo models of stroke.
@ast
Protective effects of PJ34, a ...... and in vivo models of stroke.
@en
prefLabel
Protective effects of PJ34, a ...... and in vivo models of stroke.
@ast
Protective effects of PJ34, a ...... and in vivo models of stroke.
@en
P2093
P1476
Protective effects of PJ34, a ...... and in vivo models of stroke.
@en
P2093
Abdelkarim GE
Katchanov J
P304
P577
2001-03-01T00:00:00Z